Simpson Thacher recently represented the underwriters J.P. Morgan Securities LLC, Cowen and Company, LLC, Piper Sandler & Co. and BMO Capital Markets Corp. in connection with the registered follow-on offering of 7,895,522 shares of Class A common stock by Nuvalent, Inc. (“Nuvalent”). The offering raised approximately $264.5 million in gross proceeds.
Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.
The Simpson Thacher team included Art Robinson, John O’Connell, John Ericson, Carlie Passes and Shin Song (Capital Markets); Drew Purcell and Michael Mann (Tax); Vanessa Burrows (Healthcare); Andrew Blau, Scott Schilson (ECEB); Michael Isby (Environmental); Abram Ellis and Christine Tillema (Regulatory); Corina McIntyre (IP); and Andrew Pagliughi (FINRA and Blue Sky).